Jump Financial’s TG Therapeutics TGTX Stock Holding History

Jump Financial’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$430K	Sell	7,832 -40,061	-84%	-$1.64M	﹤0.01%	1517
2026 Q1	$1.59M	Buy	+47,893	New	+$1.43M	0.02%	749
2025 Q4	–	Sell	-595,356	Closed	-$21.5M	–	2293
2025 Q3	$21.5M	Buy	595,356 +275,334	+86%	+$9.07M	0.26%	85
2025 Q2	$11.5M	Buy	320,022 +270,922	+552%	+$10.1M	0.13%	210
2025 Q1	$1.94M	Buy	+49,100	New	+$1.65M	0.03%	590
2024 Q3	–	Sell	-309,004	Closed	-$5.5M	–	2114
2024 Q2	$5.5M	Buy	+309,004	New	+$4.93M	0.11%	207
2023 Q4	–	Sell	-472,972	Closed	-$3.95M	–	2238
2023 Q3	$3.95M	Buy	472,972 +366,012	+342%	+$5.1M	0.15%	162
2023 Q2	$2.66M	Buy	+106,960	New	+$2.76M	0.1%	277
2022 Q2	–	Sell	-114,800	Closed	-$1.09M	–	2020
2022 Q1	$1.09M	Buy	+114,800	New	+$1.33M	0.05%	495
2021 Q1	–	Sell	-23,143	Closed	-$1.2M	–	1278
2020 Q4	$1.2M	Buy	+23,143	New	+$782K	0.2%	118

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jump Financial's TGTX Position: Q2 2026 in Review

Jump Financial reduced its TG Therapeutics (TGTX) stake by 84% in Q2 2026, selling an estimated $1.64M and leaving 7,832 shares worth $430K. The position accounts for ﹤0.01% of the portfolio, ranked #1517.

Jump Financial first reported a position in TGTX in Q4 2020 and has held it in 10 quarters since. The position peaked at $21.5M in Q3 2025. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Jump Financial held 7,832 shares of TG Therapeutics worth $430K as of Q2 2026.
Jump Financial sold 40,061 TG Therapeutics shares in Q2 2026, an estimated $1.64M.
TG Therapeutics made up ﹤0.01% of Jump Financial's portfolio in Q2 2026, its #1517 holding.
Jump Financial first reported a position in TG Therapeutics in Q4 2020 and has held it in 10 quarters since.
Jump Financial's TG Therapeutics position peaked at $21.5M in Q3 2025.
428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.